Clinical Trial Update: A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing subcutaneous versus intravenous rituximab in follicular non-Hodgkin's lymphoma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin's Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2015-08-05